The United Stated Department of Health and Human Services (HHS) is seeking Good Laboratory Practices (GLP) facilities to support establishing new animal tests/models for the development of biological medical countermeasures against biological threats, influenza and emerging infectious diseases.
Officials are seeking GLP laboratories that will provide the capability of nonclinical animal studies, analytical services and toxicology services in support of the Biomedical Advanced Research and Development Authority (BARDA). During these models, the challenge dose generally should be the same as that which produces the human disease or condition and the pathophysiological mechanism of its toxicity should be reasonably well understood and mimic the human disease as closely as possible.
HHS, through BARDA and the Office of Acquisitions Management, Contracts and Grants (AMCG), anticipates as many as 12 contract awards will be made to establish capabilities in toxicology, analytical services and nonclinical (animal) testing through indefinite delivery quantity contracts. The anticipated period for these contracts is expected to last up to 60 months.
For eligibility, laboratories must meet certain criterion for awards, including GLP capabilities, Association for the Assessment and Accreditation of Laboratory Animal Care International accreditation, and USDA facility licenses, as well as federal, state, and local licenses required for the handling/storage of selected agents.